IMXI:NASDAQInternational Money Express, Inc. Analysis
Data as of 2026-04-10 - not real-time
$15.81
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
International Money Express (IMXI) is trading at $15.81, just above its 20‑day SMA of $15.80 and comfortably within a narrow 30‑day volatility band of ~2.9%. The stock shows a bullish trend direction but the MACD histogram has turned negative, signaling short‑term weakness, while the RSI sits at a neutral 56. Recent insider buying by CEO Robert Lisy adds a positive sentiment cue, yet the latest earnings report missed EPS expectations and revenue fell 10.5% year‑over‑year. Technical support sits at $15.73 and resistance at $15.90, leaving limited upside of roughly 1‑2%.
Fundamentally, IMXI trades at a forward PE of 8.3 versus an industry average of 34, suggesting relative cheapness, but the DCF fair value of $4.80 marks the stock as severely overvalued at current levels. The company carries a high debt‑to‑equity ratio of 134% and a modest free cash flow generation, while operating in a heavily regulated, globally dispersed remittance market that adds regulatory and geographic risk. With no dividend and a “hold” analyst consensus, the balance of technical modesty, earnings miss, and elevated debt points to a cautious stance.
Fundamentally, IMXI trades at a forward PE of 8.3 versus an industry average of 34, suggesting relative cheapness, but the DCF fair value of $4.80 marks the stock as severely overvalued at current levels. The company carries a high debt‑to‑equity ratio of 134% and a modest free cash flow generation, while operating in a heavily regulated, globally dispersed remittance market that adds regulatory and geographic risk. With no dividend and a “hold” analyst consensus, the balance of technical modesty, earnings miss, and elevated debt points to a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Insider purchase by CEO signals confidence
- Technical support near current price
- Q1 earnings miss and revenue decline
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- DCF indicates significant overvaluation
- High debt‑to‑equity ratio
- Stable but low volume liquidity
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Elevated regulatory and geographic exposure
- Weak revenue growth trajectory
- Heavy leverage limiting financial flexibility
Key Metrics & Analysis
Financial Health
Revenue Growth-10.50%
Profit Margin5.38%
P/E Ratio14.6
ROE22.08%
ROA9.10%
Debt/Equity134.44
P/B Ratio2.9
Op. Cash Flow$36.9M
Free Cash Flow$14.2M
Industry P/E34.1
Technical Analysis
TrendBullish
RSI56.6
Support$15.73
Resistance$15.90
MA 20$15.80
MA 50$15.71
MA 200$14.29
MACDBearish
VolumeStable
Fear & Greed Index87.27
Valuation
Fair Value$4.80
Target Price$16.00
Upside/Downside1.23%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.37
Volatility2.86%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.